Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$3.44M$3.44M+156.4% vs Q1 2017 Net Income-$8.71M-$8.71MN/M vs Q1 2017 EPS Diluted-$0.17-$0.17N/M vs Q1 2017 Operating Income-$8,136,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived$30,925,000+20.8% Margins · derivedOperating margin-236.2%+359.9 pt vs Q1 2017
Net margin-253.0%+342.2 pt vs Q1 2017
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end